Bundibugyo Ebola Outbreak Explained: Why WHO Declared a PHEIC and Serum Institute of India Is Racing to Make the ChAdOx1 Vaccine

Ebola virus disease (EVD): EVD is a severe, often fatal viral haemorrhagic fever affecting humans and other primates. The virus belongs to the family Filoviridae (filoviruses, named for their thread-like shape) and the genus Orthoebolavirus. It was first identified in 1976 in two near-simultaneous outbreaks — one near the Ebola River in Zaire (today the DRC), which gave the virus its name, and one in what is now South Sudan. Because Ebola is one of the deadliest known pathogens, the virus is handled only in Biosafety Level 4 (BSL-4) laboratories, the highest containment category.

The six species of Ebola virus: Scientists recognise six species of ebolaviruses, named after the places where they were first found. These are Zaire ebolavirus (EBOV) — the deadliest, responsible for the 2014–16 West Africa epidemic; Sudan ebolavirus (SUDV); Bundibugyo ebolavirus (BDBV); Taï Forest ebolavirus (TAFV); Reston ebolavirus (RESTV) — which infects animals but is not known to cause disease in humans; and Bombali ebolavirus (BOMV), discovered in bats in 2018 with pathogenicity in humans still unknown.

The Bundibugyo strain (BDBV): This is the strain driving the current outbreak. It is named after the Bundibugyo district of western Uganda, where it was first detected in 2007. It is a rarer strain than Zaire, and historically has a somewhat lower case fatality rate (around 37%, against roughly 50% on average for EVD and up to 76% for the Zaire strain). The crucial difference for the present crisis is that, unlike the Zaire strain, there is no vaccine or treatment specifically approved for Bundibugyo — which is precisely why containment is so difficult.

The natural reservoir: The virus is believed to circulate naturally in fruit bats of the Pteropodidae family, which carry it without falling ill. The virus "spills over" into humans through contact with infected wild animals — bats, non-human primates (chimpanzees, gorillas, monkeys), forest antelope or porcupines — often via the hunting or handling of "bushmeat."

Human-to-human transmission: Once in the human population, Ebola spreads through direct contact with the blood, secretions, organs or other bodily fluids of an infected (living or dead) person, and with surfaces or materials such as bedding and clothing contaminated by these fluids. Importantly, Ebola is NOT airborne and is generally not contagious before symptoms appear — a key fact that shapes the containment strategy.

Incubation, symptoms and the burial problem: The incubation period ranges from 2 to 21 days. Symptoms begin like a flu — fever, fatigue, muscle pain, headache — and can progress to vomiting, diarrhoea, organ damage and, in severe cases, internal and external bleeding (haemorrhage). Because dead bodies remain highly infectious, traditional burial practices that involve washing and touching the deceased are a major source of new infections — making "safe and dignified burials" central to any Ebola response.

The definition: A Public Health Emergency of International Concern (PHEIC) is the highest level of alarm that WHO can sound. It is defined as an extraordinary event that constitutes a public health risk to other states through the international spread of disease, and which potentially requires a coordinated international response.

The legal basis — IHR (2005): The PHEIC is declared by the WHO Director-General under the International Health Regulations (2005), a legally binding instrument on 196 States Parties (including India). The IHR aim to prevent and respond to the international spread of disease while avoiding unnecessary interference with trade and travel. The Director-General takes this decision after convening an IHR Emergency Committee of independent experts. In the current case, the declaration was made on 17 May 2026.

PHEIC vs "pandemic emergency": Following amendments to the IHR adopted in 2024, a new, higher tier called a "pandemic emergency" was introduced. WHO clarified that the Bundibugyo outbreak qualifies as a PHEIC but does NOT meet the criteria for a pandemic emergency. The risk was assessed as very high nationally (DRC), high regionally, and low globally.

Past PHEICs: For perspective, previous PHEIC declarations include H1N1 influenza (2009), polio (2014), the West Africa Ebola epidemic (2014), Zika (2016), the DRC Ebola outbreak (2019), COVID-19 (2020) and Mpox (2022 and 2024).

Why is this outbreak so hard to control? (The conflict–health nexus)

Armed conflict: The epicentre lies in the conflict-ridden east of the DRC. Ituri province has faced attacks by the Allied Democratic Forces (ADF), an Islamist rebel group; while North Kivu and South Kivu are partly controlled by the Rwanda-backed M23 rebels. Health workers cannot safely reach patients where there is active fighting.

Displacement and distrust: The region hosts one of the world's largest humanitarian crises, with millions of people displaced. Communities, weary of conflict and outside intervention, often distrust health authorities — which delays case reporting and contact tracing. Reports describe health staff working with scant or even expired protective equipment.

Spread before detection: The outbreak is believed to have spread for weeks before being formally identified, allowing it to outpace the response. WHO chief Tedros stressed that the response had not kept pace with one of the fastest-spreading Ebola outbreaks on record.

The transparency argument: As the outbreak grew, Uganda and Rwanda closed their borders, and the United States announced restrictions on entry of certain travellers who had recently visited the DRC, Uganda or South Sudan. WHO's position — consistent with the design of the IHR — is that such blanket border closures and travel bans are largely ineffective at stopping the spread and may be counter-productive, because they discourage countries and communities from being transparent about cases. The IHR specifically seeks responses that do not unnecessarily disrupt international traffic.

The vaccine gap: Approved Ebola vaccines (such as Ervebo, the rVSV-ZEBOV single-dose vaccine, and a two-dose regimen) protect only against the Zaire strain. Because the current outbreak is the Bundibugyo strain, these licensed products do not directly apply, leaving the world without an off-the-shelf vaccine or therapeutic for this specific strain.

The candidates being raced: WHO convened its R&D Blueprint advisory groups to prioritise candidates. The most promising long-term option was judged to be the single-dose rVSV Bundibugyo vaccine developed by the International AIDS Vaccine Initiative (IAVI), which may need 7–9 months to be trial-ready. The fastest option is the ChAdOx1 Bundibugyo (ChAdOx1 BDBV) vaccine, which could be ready for clinical efficacy assessment in just 2–3 months.

The India connection — Serum Institute of India (SII): The ChAdOx1 BDBV vaccine is being developed by Oxford University and manufactured by the Serum Institute of India (SII), Pune — the world's largest vaccine maker by volume. It uses the ChAdOx1 viral-vector platform, the same technology behind the Oxford/AstraZeneca COVID-19 vaccine (made in India as Covishield). SII began producing doses under its "emergency response framework," working with the Coalition for Epidemic Preparedness Innovations (CEPI) and Oxford as soon as the outbreak emerged.

Other therapeutics: Researchers are also studying antibodies derived from Bundibugyo survivors (one candidate showed strong protection in animal studies), and Gilead's experimental antiviral obeldesivir is being considered for use after exposure.

What is the larger Indian and global significance? (Value addition for Mains)

India's vaccine diplomacy and security: India is often called the "pharmacy of the world," and SII's role in the ChAdOx1 effort underlines India's centrality to global vaccine security — a continuation of the "Vaccine Maitri" approach seen during COVID-19. Strengthening this capacity advances India's soft power and its leadership in the Global South.

India's own epidemic preparedness: India operates a high-containment BSL-4 laboratory at the ICMR–National Institute of Virology (NIV), Pune, capable of handling dangerous pathogens; the National Centre for Disease Control (NCDC) leads surveillance, and the Integrated Disease Surveillance Programme (IDSP) tracks outbreaks. India is a State Party to the IHR (2005) and must maintain core capacities for detection and response.

The One Health approach: Ebola is a zoonotic disease (spilling over from animals to humans). Its recurrence reflects the relevance of the One Health framework, which integrates human, animal and environmental health. Habitat destruction and increased human–wildlife contact heighten the risk of such spillovers — linking public health to environment and conservation.

The "Disease X" and pandemic-preparedness debate: Bundibugyo is a reminder of "Disease X" — WHO's term for an unknown pathogen that could cause a future epidemic. It strengthens the case for global mechanisms such as CEPI (which funds vaccine R&D against emerging threats), Gavi (the Vaccine Alliance), and the WHO Pandemic Agreement adopted in 2025, aimed at fairer access to vaccines and information-sharing for the next pandemic.